Exocube — exosome regenerative protocol for skin and hair
Exocube delivers high-concentration mesenchymal stem cell-derived exosomes to the face and scalp, recruiting endogenous repair mechanisms that conventional injectables cannot activate. Clinical protocol. Individually designed.
Book ConsultationWhat exosomes do — and why Exocube differs from conventional regenerative treatments
Exocube is a structured regenerative protocol that introduces MSC-derived exosomes into the dermis and scalp to initiate tissue-level repair signalling — a biological mechanism that hyaluronic acid fillers, biostimulators, and PRP cannot replicate. The distinction matters clinically: exosomes are not cells, not growth factors, and not scaffold materials. They are extracellular vesicles — 30 to 200 nm membrane-bound structures secreted by mesenchymal stem cells — that carry a highly concentrated cargo of signalling molecules: microRNA, mRNA transcripts, lipids, and proteins that regulate cellular behaviour downstream in recipient tissue.
When delivered to the dermis, MSC-derived exosomes interact with fibroblasts, keratinocytes, and endothelial cells, modulating gene expression towards proliferation and extracellular matrix synthesis. The key effectors include transforming growth factor-beta (TGF-β), vascular endothelial growth factor (VEGF), and hepatocyte growth factor (HGF) — proteins that orchestrate collagen type I deposition, neovascularisation, and keratinocyte renewal. This is not a surface-level stimulus; it is intracellular signal transduction.
On the scalp, the mechanism converges on hair follicle dermal papilla cells. Exosomes extend the anagen (growth) phase, upregulate Wnt/β-catenin signalling — the primary pathway governing follicular cycling — and suppress the DHT-mediated miniaturisation cascade. Published research by Seo et al. (Stem Cell Research & Therapy, 2022) demonstrated significant promotion of hair shaft elongation and upregulation of anagen markers in dermal papilla cultures exposed to adipose-derived exosomes, supporting the biological rationale for scalp application.
Exocube integrates percutaneous delivery — microneedling or fractional energy prior to infusion — to create transient microchannels that allow exosome penetration to the mid-dermis and hair follicle isthmus, depths that topical application alone cannot reach.
Clinical indications and patient selection for Exocube
Exocube is appropriate for patients whose primary concern is tissue quality — not just volume or wrinkle correction — and who require a regenerative approach rather than a filling or relaxing intervention. Candidate profiles evaluated at INTI clinic:
- Skin quality decline: loss of dermal thickness, luminosity, and texture in patients 40 and older; post-menopausal skin with reduced fibroblast activity; skin with photoageing or early atrophic changes
- Androgenetic alopecia: female pattern hair loss (Ludwig I–II) and male pattern loss (Norwood–Hamilton I–III); diffuse telogen effluvium following hormonal transition or systemic stress; early post-partum alopecia
- Post-procedure skin recovery: accelerating healing after ablative fractional laser, Morpheus8, or high-density Fotona; reducing downtime and optimising collagen remodelling windows
- Adjunct to fat grafting: exosome infusion in the weeks following lipofilling to support graft integration and neovascularisation at the recipient site
Patients who are not candidates:
- Active cutaneous or scalp infection (folliculitis, seborrhoeic dermatitis in acute flare)
- Immunosuppressive therapy or active autoimmune disease in relapse
- Platelet dysfunction or coagulopathy precluding microneedling
- Unrealistic outcome expectations — exosomes restore biological signalling; they do not reverse advanced scarring alopecia (Norwood V–VII) or replace surgical hair restoration in established baldness
- Pregnancy and lactation — safety data insufficient
A clinical assessment is mandatory before any session. Scalp photography and, where clinically indicated, trichoscopy are performed at baseline to establish measurable endpoints. The number of sessions and the delivery method — topical infusion versus intradermal micro-injection — are determined individually, not by a fixed package.
Protocol structure, evidence base, and what to expect across sessions
The Exocube protocol is structured across three to four sessions spaced three to four weeks apart. Each session begins with skin or scalp preparation using microneedling (0.5–1.5 mm depth for face; 1.5–2.0 mm for scalp) or a brief fractional energy pass, followed immediately by exosome infusion. The microchannel window for optimal absorption is narrow — infusion occurs within 15 to 20 minutes of channel creation before epidermal barrier restoration begins.
Session-by-session expectations in clinical practice:
Session 1 (day 0): Baseline documentation. Mild erythema for 12 to 24 hours post-microneedling. No dramatic visible change; biological signalling is initiated at the cellular level.
Session 2 (week 4): Most patients note improved skin radiance and reduction in texture irregularity. On the scalp, reduced hair shedding is typically the first subjective response — a sign that follicular cycling is stabilising.
Session 3 (week 8): Structural improvement in skin quality becomes more apparent — dermoscopic density, moisture retention, and surface luminosity. Hair regrowth at vertex or frontal zone begins to be visible in responsive candidates.
Assessment at 90 and 180 days: Comparative photographic review against baseline. Maintenance protocol (one session every three to six months) is defined at this point based on clinical response.
The evidence base for exosome therapy in aesthetic medicine is rapidly developing. A systematic review by Kim et al. (International Journal of Molecular Sciences, 2023) summarised preclinical and early clinical data confirming exosome-mediated upregulation of collagen synthesis and acceleration of wound repair. For scalp applications, the Wnt/β-catenin pathway data remains primarily preclinical — clinical evidence is preliminary and patients should be counselled accordingly. This is a field in which the science is advancing rapidly, and the clinical literature will be more definitive within three to five years.
Exocube is not a replacement for structural correction — it does not restore lost volume, reposition descended soft tissue, or reduce hyperkinetic expression lines. Its role is the restoration of biological tissue quality: the luminosity, density, and resilience that precedes or accompanies anatomical ageing changes. In patients requiring both volume restoration and regenerative input, Exocube is most effective as a combined protocol alongside the Hybrid Face Lift or fat grafting.
Dr. Thiago Perfeito
CRM-DF 23199 · Aesthetic and Regenerative Medicine
Physician with more than 10 years of practice in aesthetic and regenerative medicine. Master's degree in Aesthetic Medicine (2024). International training at Harvard Medical School and Mayo Clinic. Member of ASLMS, A4M, AMS, and NYAS. Practicing in Brasília, Lago Sul.
Learn about Dr. Thiago →Frequently asked questions about Exocube
-
What are exosomes?
Exosomes are extracellular vesicles — membrane-bound particles between 30 and 200 nanometres — secreted by cells as a mode of intercellular communication. Those derived from mesenchymal stem cells carry a concentrated payload of microRNA, mRNA, growth factors, and lipids that instruct recipient cells to proliferate, synthesise collagen, and undergo repair. They are not living cells and carry no risk of cell transfer or immune rejection when sourced from certified, lyophilised preparations.
-
How is Exocube different from PRP?
Platelet-rich plasma (PRP) delivers growth factors sequestered in platelets — primarily PDGF, TGF-β, and VEGF — which stimulate tissue repair through paracrine signalling. MSC-derived exosomes operate through a different and more targeted mechanism: they enter recipient cells and modulate gene expression directly via microRNA. Exosomes also carry Wnt pathway regulators relevant to hair follicle cycling that PRP does not contain. In clinical practice, PRP and exosomes are complementary; Exocube uses exosomes as the primary biological agent.
-
What conditions respond best?
Clinical experience and published preliminary data suggest the strongest response profiles in: early to moderate androgenetic alopecia (Ludwig I–II; Norwood I–III), skin quality decline with loss of luminosity and texture in patients 40 and older, post-procedural recovery acceleration after laser or RF microneedling, and adjunct support after fat grafting. Advanced scarring alopecia or severely photodamaged skin with structural loss respond less predictably to exosome therapy alone.
-
How many sessions are needed?
The standard Exocube protocol comprises three to four sessions spaced three to four weeks apart, followed by a clinical assessment at 90 days. Maintenance sessions (one every three to six months) are recommended for patients with ongoing androgenetic alopecia or progressive skin quality decline. The precise number is determined at the initial clinical assessment — not by a fixed package — and depends on the indication, baseline severity, and treatment response.
-
Is there clinical evidence?
The evidence base is growing but remains largely preclinical and in early-phase clinical trial for aesthetic indications. Seo et al. (Stem Cell Research & Therapy, 2022) demonstrated significant follicular growth promotion in dermal papilla cultures. Kim et al. (International Journal of Molecular Sciences, 2023) systematically reviewed exosome-mediated collagen synthesis and wound repair data. Wnt/β-catenin pathway modulation for hair cycling has strong preclinical support. Patients should be counselled that this is an emerging field — the mechanism is scientifically well-founded, but large-scale randomised controlled trials are pending.
Discuss the Exocube protocol with Dr. Thiago Perfeito
Individual clinical assessment for skin and scalp regeneration in Brasília. Protocol designed around your biology, not a fixed package.